en · de · es · fr · pt
field-notes.peptides3626.com › Wiki › Background And Receptor Pharmacology — Reference Sheet

Background And Receptor Pharmacology — Reference Sheet

By Editorial Desk · published 2026-07-08 · last reviewed 2026-07-28 · Wiki

WADA raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ in preclinical models
Molecular formulaC20H24ClN3O4SReported for the parent compound
CAS Registry Number1379686-30-2Common identifier in chemical databases
AppearanceOff-white to pale yellow solidTypical research chemical solid
SolubilitySoluble in DMSO and ethanol; low in waterClass: small organic molecule

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Related pages on this site

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

Supporting material

This orchid can, however, remain in bloom for up to two months. Each individual flower can remain fresh for as long as six weeks. In addition, this plant has been found to have potential medicinal benefits; for example one research article by Harikarnpakdee and Chowjarean found it specifically aided in wound healing in humans.

A chainsaw (or chain saw) is a portable handheld power saw that cuts with a set of teeth attached to a rotating chain driven along a guide bar. Modern chainsaws are typically gasoline or electric and are used in activities such as tree felling, limbing, bucking, pruning, cutting firebreaks in wildland fire suppression, harvesting of firewood, for use in chainsaw art and chainsaw mills, for cutting concrete, and cutting ice. Precursors to modern chainsaws were first used in surgery, with patents for wood chainsaws beginning in the late 19th century. A chainsaw comprises an engine, a drive mechanism, a guide bar, a cutting chain, a tensioning mechanism, and safety features. Various safety practices and working techniques are used with chainsaws.

In early February 2025, it was reported that the USAID director of security and a deputy were put on administrative leave after they "blocked efforts by DOGE members to physically access restricted areas" in order to obtain sensitive information. The DOGE members eventually gained access to the information, which reportedly included email as well as classified information for which they did not have security clearance. And they obtained the ability to lock USAID staff out. Musk had earlier tweeted "USAID is a criminal organization" and that it is "time for it to die". Estimates do vary. Oxfam criticized Musk's policies and actions as the world's richest individual deciding "to shutter the world's largest provider of lifesaving humanitarian aid". USAID staff were instructed to keep away from USAID headquarters while hundreds of USAID staff lost access to USAID computer systems. There have been reports that China has offered to take over development projects if the United States permanently leaves. During a February 6 press conference, Secretary of State Marco Rubio stated, "If it's providing food or medicine or anything that is saving lives and is immediate and urgent, you're not included in the freeze." However, a February 8 CNN article reported that many waivers were not being acted upon because of staff placed on leave, plus payment systems had been taken over. In an interview before the February 9 Super Bowl, Trump said, "Let him take care of the few good ones", referring to Rubio.

=== Market manipulation in the UK === In February 2016, the company was fined over £37 million in the UK by the Competition and Markets Authority for paying Generics UK, Alpharma and Norton Healthcare more than £50m between 2001, and 2004, to keep generic varieties of paroxetine out of the UK market. The generics companies were fined a further £8 million. At the end of 2003, when generics became available in the UK, the price of paroxetine dropped by 70 per cent.

Sources: en.wikipedia.org

Supporting material

== Network == Today, the IIR has 59 member countries representing over two-thirds of the global population. According to their annual financial contributions to the IIR, these member countries are divided into six categories, and this determines the services they receive and their level of voting power within the IIR. Member countries take part in IIR activities via their delegates and their nominated commission members. The delegates and commission members determine IIR priorities and take part in the IIR scientific activities and working groups, and develop recommendations. Member countries are entitled to host several IIR conferences and meetings per year.

Soybean meal is a high protein source for fish and has become a substitute for traditionally used marine animal meals. Spirulina is a blue-green Cyanobacteria rich in raw protein, vitamins A, B1, B2, B6, B12, C and E, beta-carotene, color enhancing pigments, a whole range of minerals, essential fatty acids and eight amino acids required for complete nutrition. Whole wheat (carbohydrates) is not the best source of energy in fish but is an excellent source of roughage for fish such as Goldfish and Koi. It is also a natural source of vitamin E which promotes growth and enhances coloration.

Registered voters: 425,305, valid: 371,189, turnout: 87.3% To honour the exceptionally high percentage of pro-German votes in the district of Oletzko, with 2 votes for Poland compared to 28,625 for Germany, the district town Marggrabowa (i.e. Margrave town) was renamed "Treuburg" (TreueGerman = "loyalty") in 1928, with the district following this example in 1933. In the villages of Lubstynek (Klein Lobenstein), Czerlin (Klein Nappern) and Groszki (Groschken) in the District of Osterode in East Prussia (Ostróda), situated directly at the border, the majority voted for Poland and joined Poland after the plebiscite. Other Polish-majority villages were scarce but would have been more numerous if they had not been surrounded by Mazurian German disposed villages, which made a geographical connection with Poland improbable and so votes for Poland would not be useful. The strategic importance of the Prussian Eastern Railway line Danzig-Warsaw passing through the area of Soldau in the Neidenburg District caused it to be transferred to Poland without a plebiscite; it was renamed Działdowo.[1]

Villhauer at Novartis started to explore N-substituted glycinyl-cyanopyrrolidines based on the fact that DPP-4 identifies N-methylglycine as an N-terminal amino acid. This group of new cyanopyrrolidines became extremely popular field of research in the following years. Some trials with dual inhibitors of DPP-4 and vasopeptidase have been represented, since vasopeptidase inhibition is believed to enhance the antidiabetic effect of DPP-4 inhibition by stimulating insulin secretion. Vasopeptidase-inhibiting motif is connected to the DPP-4 inhibitor at the N-substituent.

=== Venom system morphology === Little is known about the venom and the venom apparatus of centipedes. Studies on venom gland described it as the cuticle and epidermis being turned inside out. The venom gland consists of many epithelial secretory units, each with its own excretory system that is shaped like valves. Centipedes of the order Scolopendromorpha have interspersed radial striated muscles between the secretory units, where one end connects to the lumen of the venom gland and the other end connects to peripheral muscles. These muscles may be used for the contraction and constriction of anthe gland during venom ejection. The venom glands of Scolopendridae species are elongated cylindrical shape, with the lumen spanning almost the entire length of the gland. The long span of the lumen likely allows greater control over the secretion of different venom components. The venom glands span along the outer curvature of trochanteroprefemur of each forcipule.

Sources: en.wikipedia.org

Notes from published material

== History == In 2018, three unrelated children who had similar symptoms of developmental delays, skeletal abnormalities, and mild dysmorphic facial features. The first patient had an autism diagnosis and mild skeletal abnormalities but was otherwise normal. The second patient had poor growth in infancy, difficulty walking, tremors, difficulty speaking, and needed to be homeschooled due to academic difficulties. The third patient had microcephaly, poor growth, and was slow to learn how to walk but was able to attend mainstream school. All three of these patients had a variety of dysmorphic facial features that none of the patients shared except for a prominent nose, wide mouth, and thin upper lip. They were identified as having a de novo mutation on their QRICH1 gene. In 2019, 2 unrelated children were identified as having VERBAS and were found to have subtle chondrodysplasia. In 2021, Fohrenbach et al. described 4 unrelated patients with VERBAS. One patient, a three-year-old, developed nephroblastoma and died from complications, suggesting that increased cancer risk may be a part of the syndrome. In 2023, a 17-year-old girl was suffering from seizures and leukodystrophy. The girl had a history of minor developmental delays and was thought to have a perinatal brain injury resulting in mild right-side paresis. Her mother shared similar dysmorphic facial features, short stature, and distractable nature, causing them to be referred to a genecist. It was discovered that they both carried a novel QRICH1-related mutation and were diagnosed with VERBRAS.

=== Early life and education === Martin Litchfield West was born on 23 September 1937 at Eltham General Hospital (Eltham, London), the elder child (there being a younger daughter, Dr Jennifer Bywaters) of civil engineer Maurice Charles West and Catherine Baker, née Stainthorpe. His parents lived at that time in Orpington, but moved in 1939 to Hampton, where his father was appointed resident engineer at the Metropolitan Water Board-operated waterworks. West's father's family were from the Home Counties, and his mother's family from Yorkshire and Durham. His paternal grandfather, Robert West, lectured in electrical engineering; his maternal grandfather, John Stainthorpe, was a railwayman from Pickering. Litchfield was the maiden name of his paternal grandmother. Aged four, West entered the private preparatory school of Denmead. At 11, he lost a scholarship at Colet Court (now St Paul's Juniors), but was offered a feepaying place instead. West discovered at Colet his interest in languages and invented at 14 a competitor of Esperanto he labelled 'Unilingua'. In 1951, he won a scholarship to the main school, St Paul's. Excelling at both linguistics and mathematics, he was advanced to the 'Upper Eighth' and sat for a scholarship to Balliol College a year early. His tutors included Donald Russell, Michael Stokes and Russell Meiggs. Among his peers were future Nobel Prize winner Anthony J. Leggett, and future Permanent Secretary Peter Gregson.

== Taxonomy == Amanita virosa was first described in 1838 by Swedish mycologist Elias Magnus Fries as Agaricus virosus, but this name is illegitimate since it had already been used for an earlier and different species. Amanita virosa was legitimately published by French mycologist Louis-Adolphe Bertillon in 1866.

Ypadú or ypadu (also known as mambé) is an unrefined, unconcentrated powder made from toasted coca leaves and the ash of various other plants. It is traditionally prepared and consumed by indigenous tribes in the Northwest Amazon. Like coca teas consumed in Peru to adapt to sickness induced by high elevation, it has a long ethnobotanical history and cultural associations.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Is SR9009 a hormone?

No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.

What is known about human use?

Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network